Macopharma
back to the interviews

THERAFLEX UV-Platelets: A breakthrough in blood safety

With Chantal Younes, Marketing Manager Blood Safety at Macopharma.

Watch the video

Chantal Younes, Marketing Manager Blood Safety at Macopharma, provides an overview of THERAFLEX UV-Platelets and the benefits it brings patients and blood transfusion services.

What is the main challenge facing hospitals and blood transfusion centres today?

CY:“It’s ensuring they can provide patients with safe, high-quality blood components. This means dealing effectively with viruses and other pathogens, while also avoiding contamination by bacteria – since platelets are kept at room temperature. They also need to comply with different regulatory environments for blood products, which might involve using an inactivation process that requires a reagent – or a system of bacterial testing.”

Why is THERAFLEX UV-Platelets a revolutionary answer to this challenge?

CY: “It is highly effective against bacteria, viruses and emerging pathogens, and unlike every other form of UV inactivation, the platelet concentrates does not require a chemical additive. This has two crucial benefits – we completely remove the risk of an adverse reaction by the patient to the reagent, and we dramatically reduce the time needed to produce a usable bag of platelet concentrate for only less than 10 minutes.”

The ability of THERAFLEX UV-Platelets to inactivate viruses such as Dengue, Chikungunya, Zika, Ebola etc. – which can be transmitted by transfusion and are usually not tested in blood centres – is hugely important.”

What does THERAFLEX UV-Platelets offer patients and hospitals?

CY: “For both, it ensures safety. Along with bacteria, the ability of THERAFLEX UV-Platelets to inactivate viruses such as Dengue, Chikungunya, Zika, Ebola etc. – which can be transmitted by transfusion and are usually not tested in blood centres – is hugely important. For hospitals, having a much faster production process means that the platelet concentrates can still be supplied ‘on demand.’ And since we also produce the disposable sets, there is always a ready supply available.”

How do you see THERAFLEX UV-Platelets evolving in the years ahead?

CY: “For the moment, we are focusing on the current clinical trial in patients, which is due to be completed at the end of the year, and a launch in 2019. However, we will continue to enhance the system and will be looking at the potential for shortening the total process time even further, making it more flexible in terms of platelets volume and concentration, and reducing the number of manual steps involved. We understand the pressures facing hospitals and transfusion centres today, and we are committed to helping them.”